Gilead Sciences | Zinsaufwendungen Für Schuld



Interest Expense On Debt Veränderung Datum
AbbVie USD 610M 19M 2024-12
Agios Pharmaceuticals 3.01M 10.05M 2024-12
ALKERMES USD 4.65M 1.35M 2024-12
Alnylam Pharmaceuticals USD 38.97M 4.6M 2024-12
Amgen USD 747M 29M 2024-12
Biogen USD 60M 200K 2024-12
BioMarin Pharmaceutical USD 2.58M 391K 2024-12
Bristol-Myers Squibb USD 494M 2M 2025-03
Eli Lilly USD 224.7M 78.4M 2024-12
Gilead Sciences USD 260M 12M 2025-03
GlaxoSmithKline 162M 11M 2025-03
Glaxosmithkline 178.05M 24.73M 2024-12
Incyte USD 660K 241K 2025-03
J&J USD 128M 9M 2025-03
Merck USD 328M 2M 2024-12
Moderna USD 6M 0 2024-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 275M 11M 2024-12
Pfizer USD 654M 85M 2025-03
PTC Therapeutics USD 43.35M 1.24M 2024-12
Regeneron Pharmaceuticals USD 8.7M 1.8M 2025-03
Sanofi 213M 151M 2025-03
Sarepta Therapeutics USD 4.92M 86K 2024-09
United Therapeutics USD 6.1M 1.8M 2025-03
Vertex Pharmaceuticals USD 2.8M 4.7M 2024-12



Gilead Sciences Zinsaufwendungen Für Schuld - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - May 2025.